GSK (LON:GSK - Get Free Report)'s stock had its "buy" rating reiterated by analysts at Shore Capital in a note issued to investors on Friday, Marketbeat.com reports. They presently have a GBX 2,000 ($26.83) target price on the stock. Shore Capital's target price indicates a potential upside of 48.59% from the stock's current price.
Other analysts have also issued research reports about the stock. JPMorgan Chase & Co. reiterated an "underweight" rating on shares of GSK in a research report on Friday. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and set a GBX 1,450 ($19.45) price target on shares of GSK in a research report on Tuesday, July 8th. Finally, Berenberg Bank reissued a "hold" rating and issued a GBX 1,600 ($21.46) price objective on shares of GSK in a research note on Friday.
Check Out Our Latest Report on GSK
GSK Stock Performance
LON GSK traded down GBX 2 ($0.03) during trading on Friday, reaching GBX 1,346 ($18.05). The company's stock had a trading volume of 1,683,255,125 shares, compared to its average volume of 25,790,002. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64. The firm has a market capitalization of £54.62 billion, a price-to-earnings ratio of 21.74, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. GSK has a 12 month low of GBX 1,242.50 ($16.67) and a 12 month high of GBX 1,678.68 ($22.52). The firm has a 50 day moving average price of GBX 1,435.32 and a 200 day moving average price of GBX 1,423.08.
GSK (LON:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The company reported GBX 44.90 ($0.60) earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, equities analysts anticipate that GSK will post 175.980975 EPS for the current fiscal year.
Insider Activity at GSK
In related news, insider Wendy Becker acquired 545 shares of the company's stock in a transaction that occurred on Friday, June 20th. The stock was acquired at an average price of GBX 1,435 ($19.25) per share, with a total value of £7,820.75 ($10,490.61). Also, insider Jonathan Symonds purchased 1,350 shares of the company's stock in a transaction dated Friday, June 20th. The shares were acquired at an average cost of GBX 1,435 ($19.25) per share, with a total value of £19,372.50 ($25,985.92). Insiders purchased a total of 1,905 shares of company stock valued at $2,732,835 in the last quarter. Insiders own 1.61% of the company's stock.
About GSK
(
Get Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Further Reading
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
